Compare General Dynamics Corporation (GD) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Novartis AG — how do they compare? General Dynamics Corporation trades at $365.8 (market cap $98.88B), while Novartis AG trades at $150.91 (market cap $287.66B). The key difference: Novartis AG is far larger — about 2.9× General Dynamics Corporation's market cap, and Novartis AG pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| GD | NVS | |
|---|---|---|
Market Cap | $98.88B | $287.66B |
Sector | Industrials | Health |
52-Week High | $376.88 | $168.62 |
52-Week Low | $297.05 | $113.50 |
Enterprise Value | $105.06B | $327.68B |
Dividend Yield | 1.74% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $366.40, down 0.84% on the day, with strong technical momentum indicated by bullish moving averages and oscillators. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $4.10 versus $3.67, continuing a trend of earnings outperformance. Revenue growth has been consistent, reaching $52.55 billion in 2025 with an 8.07% net income margin. Analyst sentiment remains positive with a $395.83 consensus price target and 53% buy ratings.
The outlook for GD is favorable given strong defense spending tailwinds and a growing $130.8 billion backlog, particularly in marine systems. However, risks include execution challenges on large contracts and potential defense budget volatility. The stock's current valuation at 23x P/E appears reasonable relative to earnings growth prospects, positioning it as a core defense holding for long-term investors.
NVS trades at $152.51, up 1.43% today, with a bearish technical signal despite strong profitability metrics including a 75.38% gross margin and 35.21% ROE. Recent earnings show mixed results, missing Q1 2026 estimates but beating Q4 2025. The company is actively expanding its oncology pipeline through acquisitions like Myricx Bio for up to $1.5 billion (Reuters, 2026-07-06).
The outlook is balanced; robust cash flow and high margins support growth, but rising debt-to-asset ratios and cautious analyst consensus (68% hold) indicate near-term headwinds. Key risks include execution of pipeline developments and competitive pressures in pharmaceuticals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
